ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014
How will physicians respond to the next influenza pandemic?
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Treating COVID-19: Targeting the Host Response, Not the Virus.Life (Basel, Switzerland) · 2023Review
- Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Influenza pandemic preparedness: A special challenge for India.The Indian journal of medical research · 2019Article
- Treating the host response: an alternative way to manage Ebola in Africa and the next influenza pandemic.Journal of global health · 2019Review
- What treating Ebola means for pandemic influenza.Journal of public health policy · 2018Article
- Clinician-initiated research on treating the host response to pandemic influenza.Human vaccines & immunotherapeutics · 2018Article
- Surviving Deadly Lung Infections: Innate Host Tolerance Mechanisms in the Pulmonary System.Frontiers in immunology · 2018Review
- Influenza, evolution, and the next pandemic.Evolution, medicine, and public health · 2018Review
- Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.Annals of translational medicine · 2016Review
- Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.The Lancet. Infectious diseases · 2016Review
- The transition from a rural to an urban environment alters expression of the human Ebola virus receptor Neiman-Pick C1: implications for the current epidemic in West Africa.Cell stress & chaperones · 2015Article
- Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse.Science China. Life sciences · 2015Article
- Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations.Open forum infectious diseases · 2015Article
- The dysfunctional host response to influenza A H7N9: a potential treatment option?Critical care (London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of the H7N9 virus in China is another reminder of the threat of a global influenza pandemic. Many believe we could confront a pandemic by expanding our capacity to provide timely supplies of affordable pandemic vaccines and antiviral agents. Experience in 2009 demonstrated that this cannot and will not be done. Consequently, physicians may have little more to offer their patients than they had in the 1918 pandemic. Fortunately, several modern drugs (eg, statins, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors) can modify the host response to inflammatory illness, and laboratory and clinical studies suggest they might be used to treat pandemic patients. Unfortunately, little attention has been given to the research needed to support their use in patient care. There is no guarantee these drugs will work, but physicians will never know unless those responsible for pandemic preparedness recognize and act on the extraordinary possibility that they might save lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.